Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
1. TERN-601 shows 4.6% weight loss; high treatment discontinuation at 12%. 2. Grade 3 liver enzyme elevations noted; two cases drug-related. 3. Company will not advance TERN-601 or invest in metabolic assets. 4. Focus shifts to TERN-701 for chronic myeloid leukemia with upcoming data. 5. Future detailed results of TERN-601 Phase 2 trial will be published.